Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Paolo Peterlongo(IFOM), Javier Benı́tez(Spanish National Cancer Research Centre), Logan C. Walker(Churchill Hospital), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Alex Miron(Case Western Reserve University), Stefan Wilkening(German Cancer Research Center), Elizabeth J. van Rensburg(University of Pretoria), Jan Lubiński(Tumour Institute of Tuscany), Thomas van Overeem Hansen(University of Copenhagen), Bent Ejlertsen, Ana-Teresa Maia(Cancer Research UK), Felicity Lose(QIMR Berghofer Medical Research Institute), Ana Osório(Spanish National Cancer Research Centre), Marco Montagna(Azienda Ospedale - Università Padova), Robert L. Nussbaum(National Institutes of Health), Douglas F. Easton(University of Cambridge), Yuan Chun Ding(University of Copenhagen), Anna Jakubowska(Pomeranian Medical University), Jacques Simard(Université Laval), Ramūnas Janavičius(Vilnius University), Susan M. Domchek(University City Science Center), Ute Hamann(German Cancer Research Center), Katherine L. Nathanson(Translational Therapeutics (United States)), Saundra S. Buys(University of Utah), Sandra Oršulić(Cedars-Sinai Medical Center), Anne‐Marie Gerdes(Copenhagen University Hospital), Laura Matricardi(Istituto Oncologico Veneto), Anja Rudolph(Institut für Qualität im Management (Germany)), Cristina Martínez-Bouzas(Hospital Clínico Universitario Lozano Blesa), Frederieke H. van der Baan(Dutch Cancer Society), Bowang Chen(German Cancer Research Center), Matti A. Rookus(The Netherlands Cancer Institute), Melissa C. Southey(The University of Melbourne), Cecilia M. Dorfling(QIMR Berghofer Medical Research Institute), Wendy K. Chung(Columbia University), Kirsten B. Moysich(Roswell Park Comprehensive Cancer Center), Banu K. Arun(The University of Texas MD Anderson Cancer Center), Amanda B. Spurdle(QIMR Berghofer Medical Research Institute), Beth Y. Karlan(Cedars-Sinai Medical Center), Lars Jønson(Copenhagen University Hospital), Jenny Lester(Cedars-Sinai Medical Center), Timothy R. Rebbeck(University of Pennsylvania), Susan L. Neuhausen(City of Hope), Olufunmilayo I. Olopade(Cancer Genetics (United States)), Penny Soucy(University of Cambridge), Rita K. Schmutzler(University of Cologne), David E. Goldgar(University of Utah), E. Gómez(Maastricht University Medical Centre), Jenny Chang-Claude(German Cancer Research Center), Marjanka K. Schmidt(University of Cambridge)
Cited by 25
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k